Major R&D Pipeline: 3ADCs

ENHERTU®: Performance in Each Region Steady increase in product sales due to market penetration in launched countries and expansion in market Product sales: FY2021 Q1 Results 13.0 Bn JPY (YOY +7.7 Bn JPY) 61.0 Bn JPY (YoY +30.9 Bn JPY) Daiichi-Sankyo >ENHERTU trastuzumab deruxtecan FY2021 Forecast US (HER2+ Breast Cancer 3L, HER2+ Gastric Cancer 2L) Europe (HER2+ Breast Cancer 3L) Steady growth in the market New patient share as planned ➤ Outlets purchasing as planned Accumulated total of outlets purchasing Steady expansion in the market ➤ EU: Launched in FY2020 Q4 ➤ UK: Launched in FY2021 Q1 Japan (HER2+ Breast Cancer 3L, HER2+ Gastric Cancer 3L) Steady growth in the market New patient share as planned Outlets purchasing as planned Accumulated total of outlets purchasing 2020 Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec 2021 Jan Feb Mar Apr May Jun 2020 May Jun Jul Aug Sep Oct Nov Dec Jan Feb Mar Apr May Jun 12

View entire presentation